# A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

> **NCT05868733** · PHASE2 · RECRUITING · sponsor: **International AIDS Vaccine Initiative** · enrollment: 612 (estimated)

## Conditions studied

- Lassa Fever

## Interventions

- **DRUG:** Day 1 Lower Dose (2×106 pfu)
- **DRUG:** Day 1 Higher Dose (1×107 pfu)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05868733
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-04
- **Target enrollment:** 612 (ESTIMATED)
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05868733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05868733, "A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05868733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*